Cardiovascular Diseases and Conditions Videos

In this video, Prof. Christopher P. Cannon presents an infographic on treatment persistence and non-adherence in Atherosclerotic Cardiovascular Disease.

Prof. Christopher P. Cannon

First published: July 16, 2025  

In this video, Prof. Maciej Banach discusses the 2024 recommendations on the optimal use of LLT in established ASCVD and following ACS.

First published: March 4, 2025  

In this video, Prof. Christopher Cannon and Prof. Maciej Banach discuss the current status of lipid lowering therapy with a focus on combination therapy.

First published: March 4, 2025  

In this video, Prof Stephen Nicholls discusses the future of ASCVD and Lipidology in 2025.

First published: February 24, 2025  

Prof. Christopher Cannon, Prof. Maciej Banach

First published: November 24, 2024  

In this video, Prof. Deepak L. Bhatt presents an infographic on Proprotein Convertase Subtilisin/Kexin Type 9 in Cholesterol Homeostasis, Inflammation, and Thrombosis Associated with Cardiovascular Diseases – an overview of molecular functions and therapeutic strategies.

Prof. Deepak L. Bhatt

First published: September 10, 2024  

Video highlights from the European Society of Cardiology (ESC) Congress 2024, taking place in London from August 30 to September 2. Featuring faculty members Prof Stephen Nicholls, Prof Deepak Bhatt and Prof Yi-Heng Li, these clips provide invaluable insights and updates on cardiovascular research from ESC Congress 2024.

Prof Stephen Nicholls, Prof Yi-Heng Li

First published: August 30, 2024  

In this video, Prof. Christopher Cannon provides a comprehensive overview of our infographic on the therapeutic management of dyslipidaemia. Dyslipidaemia, a key risk factor for cardiovascular diseases, is conventionally managed through therapies targeting lipoproteins such as LDL, Lp(a), IDL + VLDL through small-molecule therapeutics. Despite their effectiveness, off-target events and poor patient compliance often pose significant challenges. Hence novel therapeutics, such as small interfering RNAs, antisense oligonucleotides, and monoclonal antibodies have been developed. These advancements highlight a significant step forward in the management of dyslipidaemia. Prof. Cannon emphasizes these main points in the video, aiming to guide clinicians in optimizing lipid-lowering therapy for cardiovascular risk prevention.

Prof. Christopher Cannon

First published: August 1, 2024  

In this video, Prof. Christopher Cannon provides a comprehensive overview of our infographic on the World Heart Foundation’s Cholesterol Roadmap (2022) for the management and prevention of atherosclerotic cardiovascular disease (ASCVD). He discusses various approaches for ASCVD prevention, emphasizes regional differences in adherence to ASCVD treatment guidelines, and highlights barriers to effective risk management. This roadmap offers a scientifically sound foundation for policymakers to implement changes aimed at reducing the burden of ASCVD.

Prof. Christopher Cannon

First published: August 1, 2024  

In this video, Prof. Lale Tokgozoglu of Hacettepe University, former president of the European Atherosclerosis Society, discusses the structure, function, and genetics of Lp(a) and highlights the clinical implications of elevated Lp(a) levels. Using evidence from contemporary clinical studies, Prof. Tokgozoglu shares insights into approaches for lowering Lp(a) levels. Finally, challenges in the comprehensive understanding of the physiological and clinical implications of Lp(a) are discussed. Learning outcome – High levels of lipoprotein(a) increase the chances of experiencing heart attack, stroke, and aortic stenosis.

Prof. S. Lale Tokgözoğlu

First published: March 11, 2024  

In this video, Prof. Stephen Nicholls provides a comprehensive overview of our infographic on lipid measurements and their clinical implications, serving as a helpful resource for healthcare professionals involved in managing cardiovascular disease. Covering atherogenic dyslipidemia, lipid profile components, advanced tests, and genetic considerations, Prof. Nicholls emphasizes individualized approaches to interpreting lipid parameters based on patient demographics and risk levels. This aims to guide clinicians in optimizing lipid-lowering therapy for cardiovascular risk prevention.

First published: March 6, 2024  

In this video, we summarize the results from the SANTORINI trial which documents the effectiveness of current treatment practice in managing LDL-C levels for patients in the higher CV risk categories in and how care may be improved.

First published: July 12, 2023